Per E AndrÃ©n

List of Publications by Year
in descending order

149	5,734	66343	95266
papers	citations	42 h-index	68 g-index

158	158	158	5610
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Analytical Chemistry, 2022, 94, 1795-1803.	6.5	20
2	The involvement of cyclotides in mutual interactions of violets and the two-spotted spider mite. Scientific Reports, 2022, 12, 1914.	3.3	5
3	Well-Plate Î¼FASP for Proteomic Analysis of Single Pancreatic Islets. Journal of Proteome Research, 2022, 21, 1167-1174.	3.7	6
4	Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems. ACS Chemical Biology, 2022, 17, 147-158.	3.4	8
5	Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia. Npj Parkinson's Disease, 2022, 8, 41.	5.3	5
6	Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics. Trends in Pharmacological Sciences, 2022, 43, 740-753.	8.7	5
7	Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and Infection, 2021, 27, 1315-1321.	6.0	21
8	Mass spectrometry imaging identifies abnormally elevated brain <scp>l</scp> -DOPA levels and extrastriatal monoaminergic dysregulation in <scp>l</scp> -DOPAâ€“induced dyskinesia. Science Advances, 2021, 7, .	10.3	29
9	Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain. ACS Chemical Neuroscience, 2021, 12, 1811-1823.	3.5	17
10	Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimerâ€™s Disease Following Treatment with a Brain-Targeting Somatostatin Peptide. ACS Chemical Neuroscience, 2021, 12, 2529-2541.	3.5	11
11	Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging. Nature Protocols, 2021, 16, 3298-3321.	12.0	27
12	Cyclotide host-defense tailored for species and environments in violets from the Canary Islands. Scientific Reports, 2021, 11, 12452.	3.3	12
13	TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition. Biological Psychiatry, 2021, 90, 16-27.	1.3	9
14	Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the bloodâ€“brain barrier. Molecular Psychiatry, 2021, 26, 7732-7745.	7.9	14
15	Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine, 2021, 73, 103652.	6.1	15
16	Holistic Characterization of a Salmonella Typhimurium Infection Model Using Integrated Molecular Imaging. Journal of the American Society for Mass Spectrometry, 2021, 32, 2791-2802.	2.8	6
17	Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 43-53.	1.4	13
18	Âμ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease. Journal of Neuroscience, 2020, 40, 6812-6819.	3.6	24

#	Article	IF	Citations
19	Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers. Analytical Chemistry, 2020, 92, 14676-14684.	6.5	22
20	Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses. Frontiers in Pharmacology, 2020, 11, 304.	3.5	5
21	Bromopyrylium Derivatization Facilitates Identification by Mass Spectrometry Imaging of Monoamine Neurotransmitters and Small Molecule Neuroactive Compounds. Journal of the American Society for Mass Spectrometry, 2020, 31, 2553-2557.	2.8	21
22	Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy. Neurobiology of Disease, 2020, 137, 104738.	4.4	36
23	Deficits in Motor Performance, Neurotransmitters and Synaptic Plasticity in Elderly and Experimental Parkinsonian Mice Lacking GPR37. Frontiers in Aging Neuroscience, 2020, 12, 84.	3.4	14
24	Î±-synucleinâ^'lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15226-15235.	7.1	33
25	Detection of a High-Turnover Serotonin Circuit in the Mouse Brain Using Mass Spectrometry Imaging. IScience, 2019, 20, 359-372.	4.1	33
26	Comprehensive mapping of neurotransmitter networks by MALDIâ€“MS imaging. Nature Methods, 2019, 16, 1021-1028.	19.0	148
27	Insomnia in pediatric obsessiveâ€“compulsive disorder: prevalence and association with multimodal treatment outcomes in a naturalistic clinical setting. Sleep Medicine, 2019, 56, 104-110.	1.6	15
28	Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition. Neuropsychopharmacology, 2019, 44, 2091-2098.	5.4	22
29	A Space Efficient Direct Access Data Compression Approach for Mass Spectrometry Imaging. Analytical Chemistry, 2018, 90, 3676-3682.	6.5	6
30	Brain Tissue Sample Stabilization and Extraction Strategies for Neuropeptidomics. Methods in Molecular Biology, 2018, 1719, 41-49.	0.9	14
31	Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging. Analytical Chemistry, 2018, 90, 6051-6058.	6.5	56
32	A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability. NeuroImage, 2018, 172, 808-816.	4.2	25
33	Uncovering the regional localization of inhaled salmeterol retention in the lung. Drug Delivery, 2018, 25, 838-845.	5.7	17
34	Peptide ion channel toxins from the bootlace worm, the longest animal on Earth. Scientific Reports, 2018, 8, 4596.	3.3	22
35	How Does the Sweet Violet (Viola odorata L.) Fight Pathogens and Pests â€“ Cyclotides as a Comprehensive Plant Host Defense System. Frontiers in Plant Science, 2018, 9, 1296.	3.6	51
36	Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or Î²-Phenylethylamine. Frontiers in Pharmacology, 2018, 9, 166.	3.5	14

#	Article	IF	Citations
37	Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB). Bioorganic and Medicinal Chemistry, 2017, 25, 897-911.	3.0	10
38	Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axis. Scientific Reports, 2017, 7, 6352.	3.3	22
39	Mass spectrometry imaging identifies palmitoylcarnitine as an immunological mediator during Salmonella Typhimurium infection. Scientific Reports, 2017, 7, 2786.	3.3	31
40	msIQuant â€“ Quantitation Software for Mass Spectrometry Imaging Enabling Fast Access, Visualization, and Analysis of Large Data Sets. Analytical Chemistry, 2016, 88, 4346-4353.	6.5	109
41	Direct imaging of elemental distributions in tissue sections by laser ablation mass spectrometry. Methods, 2016, 104, 86-92.	3.8	15
42	Simultaneous imaging of multiple neurotransmitters and neuroactive substances in the brain by desorption electrospray ionization mass spectrometry. NeuroImage, 2016, 136, 129-138.	4.2	68
43	Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Science Translational Medicine, 2016, 8, 325ra17.	12.4	171
44	Exemplifying the Screening Power of Mass Spectrometry Imaging over Label-Based Technologies for Simultaneous Monitoring of Drug and Metabolite Distributions in Tissue Sections. Journal of Biomolecular Screening, 2016, 21, 187-193.	2.6	33
45	Association of chromosome 19 to lung cancer genotypes and phenotypes. Cancer and Metastasis Reviews, 2015, 34, 217-226.	5.9	26
46	Mass Spectrometry Imaging in Drug Development. Analytical Chemistry, 2015, 87, 1437-1455.	6.5	153
47	Pyrylium Salts as Reactive Matrices for MALDI-MS Imaging of Biologically Active Primary Amines. Journal of the American Society for Mass Spectrometry, 2015, 26, 934-939.	2.8	89
48	Investigating Nephrotoxicity of Polymyxin Derivatives by Mapping Renal Distribution Using Mass Spectrometry Imaging. Chemical Research in Toxicology, 2015, 28, 1823-1830.	3.3	36
49	An introduction to MS imaging in drug discovery and development. Bioanalysis, 2015, 7, 2621-2627.	1.5	4
50	Discussion point: reporting guidelines for mass spectrometry imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 2035-2045.	3.7	51
51	Use of ENCODE Resources to Characterize Novel Proteoforms and Missing Proteins in the Human Proteome. Journal of Proteome Research, 2015, 14, 603-608.	3.7	17
52	Asymmetry of the Endogenous Opioid System in the Human Anterior Cingulate: a Putative Molecular Basis for Lateralization of Emotions and Pain. Cerebral Cortex, 2015, 25, 97-108.	2.9	41
53	MALDI Mass Spectrometry Imaging of Dopamine and PET D1 and D2 Receptor Ligands in Rodent Brain Tissues. Neuromethods, 2015, , 177-196.	0.3	1
54	Identification of best indicators of peptide-spectrum match using a permutation resampling approach. Journal of Bioinformatics and Computational Biology, 2014, 12, 1440001.	0.8	3

#	Article	IF	Citations
55	Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease, 2014, 62, 307-312.	4.4	25
56	Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections. Neuron, 2014, 84, 697-707.	8.1	188
57	Mass Spectrometry Imaging of Cassette-Dosed Drugs for Higher Throughput Pharmacokinetic and Biodistribution Analysis. Analytical Chemistry, 2014, 86, 8473-8480.	6.5	82
58	Mass Spectrometry Imaging, an Emerging Technology in Neuropsychopharmacology. Neuropsychopharmacology, 2014, 39, 34-49.	5.4	79
59	Accurate Assignment of Significance to Neuropeptide Identifications Using Monte Carlo K-Permuted Decoy Databases. PLoS ONE, 2014, 9, e111112.	2.5	2
60	Developments in biobanking workflow standardization providing sample integrity and stability. Journal of Proteomics, 2013, 95, 38-45.	2.4	56
61	Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium. Journal of Proteome Research, 2013, 12, 135-150.	3.7	16
62	Neurotoxin-Induced Neuropeptide Perturbations in Striatum of Neonatal Rats. Journal of Proteome Research, 2013, 12, 1678-1690.	3.7	41
63	Chronic Nicotine Treatment Impacts the Regulation of Opioid and Non-opioid Peptides in the Rat Dorsal Striatum. Molecular and Cellular Proteomics, 2013, 12, 1553-1562.	3.8	22
64	High Identification Rates of Endogenous Neuropeptides from Mouse Brain. Journal of Proteome Research, 2012, 11, 2819-2827.	3.7	36
65	Deuterated Matrix-Assisted Laser Desorption Ionization Matrix Uncovers Masked Mass Spectrometry Imaging Signals of Small Molecules. Analytical Chemistry, 2012, 84, 7152-7157.	6.5	47
66	Controlled-pH Tissue Cleanup Protocol for Signal Enhancement of Small Molecule Drugs Analyzed by MALDI-MS Imaging. Analytical Chemistry, 2012, 84, 4603-4607.	6.5	56
67	Evaluation of Database Search Programs for Accurate Detection of Neuropeptides in Tandem Mass Spectrometry Experiments. Journal of Proteome Research, 2012, 11, 6044-6055.	3.7	17
68	Extensive Characterization of Tupaia belangeri Neuropeptidome Using an Integrated Mass Spectrometric Approach. Journal of Proteome Research, 2012, 11, 886-896.	3.7	27
69	Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology, 2012, 62, 347-357.	4.1	27
70	Going forward: Increasing the accessibility of imaging mass spectrometry. Journal of Proteomics, 2012, 75, 5113-5121.	2.4	24
71	Conductive carbon tape used for support and mounting of both whole animal and fragile heat-treated tissue sections for MALDI MS imaging and quantitation. Journal of Proteomics, 2012, 75, 4912-4920.	2.4	51
72	Preface. Journal of Proteomics, 2012, 75, 4881-4882.	2.4	2

#	Article	IF	Citations
73	Novel mass spectrometry imaging software assisting labeled normalization and quantitation of drugs and neuropeptides directly in tissue sections. Journal of Proteomics, 2012, 75, 4941-4951.	2.4	134
74	In Situ Mass Spectrometry Imaging and Ex Vivo Characterization of Renal Crystalline Deposits Induced in Multiple Preclinical Drug Toxicology Studies. PLoS ONE, 2012, 7, e47353.	2.5	40
75	The significance of ambientâ€temperature on pharmaceutical and endogenous compound abundance and distribution in tissues sections when analyzed by matrixâ€assisted laser desorption/ionization mass spectrometry imaging. Rapid Communications in Mass Spectrometry, 2012, 26, 494-498.	1.5	33
76	High Speed Data Processing for Imaging MS-Based Molecular Histology Using Graphical Processing Units. Journal of the American Society for Mass Spectrometry, 2012, 23, 745-752.	2.8	14
77	Qualitative and Quantitative MALDI Imaging of the Positron Emission Tomography Ligands Raclopride (a D2 Dopamine Antagonist) and SCH 23390 (a D1 Dopamine Antagonist) in Rat Brain Tissue Sections Using a Solvent-Free Dry Matrix Application Method. Analytical Chemistry, 2011, 83, 9694-9701.	6.5	86
78	Identification of Proteinâ€Protein Interactions by Surface Plasmon Resonance followed by Mass Spectrometry. Current Protocols in Protein Science, 2011, 65, Unit19.21.	2.8	21
79	Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. Neurochemistry International, 2011, 59, 280-289.	3.8	25
80	The transition of the European Proteomics Association into the future. Journal of Proteomics, 2011, 75, 18-22.	2.4	0
81	Neuropeptide profiling of the bovine hypothalamus: Thermal stabilization is an effective tool in inhibiting postâ€mortem degradation. Proteomics, 2011, 11, 1264-1276.	2.2	27
82	Distribution, level, pharmacology, regulation, and signaling of 5â€HT₆ receptors in rats and marmosets with special reference to an experimental model of parkinsonism. Journal of Comparative Neurology, 2011, 519, 1816-1827.	1.6	13
83	Impact of Temperature Dependent Sampling Procedures in Proteomics and Peptidomics â€“ A Characterization of the Liver and Pancreas Post Mortem Degradome. Molecular and Cellular Proteomics, 2011, 10, M900229-MCP200.	3.8	35
84	Essential tactics of tissue preparation and matrix nano-spotting for successful compound imaging mass spectrometry. Journal of Proteomics, 2010, 73, 1270-1278.	2.4	34
85	Proteomic profiling of the Baltic Sea cyanobacterium Nodularia spumigena strain AV1 during ammonium supplementation. Journal of Proteomics, 2010, 73, 1670-1679.	2.4	5
86	Neuropeptidomic analysis of the embryonic Japanese quail diencephalon. BMC Developmental Biology, 2010, 10, 30.	2.1	11
87	In vivo investigation of brain and systemic ketobemidonemetabolism. Analyst, The, 2010, 135, 405-413.	3.5	4
88	Fine Mapping the Spatial Distribution and Concentration of Unlabeled Drugs within Tissue Micro-Compartments Using Imaging Mass Spectrometry. PLoS ONE, 2010, 5, e11411.	2.5	192
89	In Vitro Neurotoxicity of PBDE-99: Immediate and Concentration-Dependent Effects on Protein Expression in Cerebral Cortex Cells. Journal of Proteome Research, 2010, 9, 1226-1235.	3.7	26
90	Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease. Molecular and Cellular Proteomics, 2009, 8, 1094-1104.	3.8	47

#	Article	IF	Citations
91	Development and Evaluation of Normalization Methods for Label-free Relative Quantification of Endogenous Peptides. Molecular and Cellular Proteomics, 2009, 8, 2285-2295.	3.8	91
92	Coupling surface plasmon resonance to mass spectrometry to discover novel proteinâ€“protein interactions. Nature Protocols, 2009, 4, 1023-1037.	12.0	34
93	Heat Stabilization of the Tissue Proteome: A New Technology for Improved Proteomics. Journal of Proteome Research, 2009, 8, 974-981.	3.7	137
94	A Quantitative Peptidomic Analysis of Peptides Related to the Endogenous Opioid and Tachykinin Systems in Nucleus Accumbens of Rats Following Naloxone-Precipitated Morphine Withdrawal. Journal of Proteome Research, 2009, 8, 1091-1098.	3.7	23
95	MALDI Imaging and Profiling Mass Spectrometry in Neuroproteomics. Frontiers in Neuroscience, 2009, , 115-134.	0.0	1
96	Method development for identification of ketobemidone metabolites in microdialysate samples by coupled-column capillary liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography A, 2008, 1189, 503-513.	3.7	11
97	Exposure to brominated flame retardant PBDE-99 affects cytoskeletal protein expression in the neonatal mouse cerebral cortex. NeuroToxicology, 2008, 29, 628-637.	3.0	62
98	Neurokinin B/NK3 receptors exert feedback inhibition on l-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology, 2008, 54, 1143-1152.	4.1	22
99	Validation of Endogenous Peptide Identifications Using a Database of Tandem Mass Spectra. Journal of Proteome Research, 2008, 7, 3049-3053.	3.7	28
100	Analytical Utility of Small Neutral Losses from Reduced Species in Electron Capture Dissociation Studied Using SwedECD Database. Analytical Chemistry, 2008, 80, 8089-8094.	6.5	42
101	Use of Surface Plasmon Resonance Coupled with Mass Spectrometry Reveals an Interaction between the Voltage-Gated Sodium Channel Type X Î±-Subunit and Caveolin-1. Journal of Proteome Research, 2008, 7, 5333-5338.	3.7	16
102	Evidence for a role of the 5-HT _{1B} receptor and its adaptor protein, p11, in <scp>l</scp> -DOPA treatment of an animal model of Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2163-2168.	7.1	109
103	Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure. PLoS ONE, 2008, 3, e1589.	2.5	45
104	Neuropeptidomics Strategies for Specific and Sensitive Identification of Endogenous Peptides. Molecular and Cellular Proteomics, 2007, 6, 1188-1197.	3.8	47
105	Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiology and Behavior, 2007, 92, 29-33.	2.1	50
106	An Automated Method for Scanning LCâ^'MS Data Sets for Significant Peptides and Proteins, Including Quantitative Profiling and Interactive Confirmation. Journal of Proteome Research, 2007, 6, 2888-2895.	3.7	19
107	Increased Striatal mRNA and Protein Levels of the Immunophilin FKBP-12 in Experimental Parkinson's Disease and Identification of FKBP-12-Binding Proteins. Journal of Proteome Research, 2007, 6, 3952-3961.	3.7	29
108	SwedCAD, a Database of Annotated High-Mass Accuracy MS/MS Spectra of Tryptic Peptides. Journal of Proteome Research, 2007, 6, 4063-4067.	3.7	28

#	Article	IF	Citations
109	Neuropeptidomics: MS Applied to the Discovery of Novel Peptides from the Brain. Analytical Chemistry, 2007, 79, 14-21.	6.5	57
110	The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2â€20 and peptides as sample quality indicators. Proteomics, 2007, 7, 4445-4456.	2.2	104
111	In Vitro Imaging Techniques in Neurodegenerative Diseases. Molecular Imaging and Biology, 2007, 9, 161-175.	2.6	28
112	Decreased Striatal Levels of PEP-19 Following MPTP Lesion in the Mouse. Journal of Proteome Research, 2006, 5, 262-269.	3.7	115
113	Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Research, 2006, 1095, 207-210.	2.2	34
114	Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics, 2006, 7, 475.	2.6	37
115	Sample pretreatment on a microchip with an integrated electrospray emitter. Electrophoresis, 2006, 27, 2075-2082.	2.4	18
116	SwePep, a Database Designed for Endogenous Peptides and Mass Spectrometry. Molecular and Cellular Proteomics, 2006, 5, 998-1005.	3.8	121
117	Electrokinetic-driven microfluidic system in poly(dimethylsiloxane) for mass spectrometry detection integrating sample injection, capillary electrophoresis, and electrospray emitter on-chip. Electrophoresis, 2005, 26, 4674-4683.	2.4	47
118	Altered extracellular striatalin vivobiotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. Journal of Mass Spectrometry, 2005, 40, 261-270.	1.6	38
119	Poly(dimethylsiloxane)-Based Microchip for Two-Dimensional Solid-Phase Extraction-Capillary Electrophoresis with an Integrated Electrospray Emitter Tip. Analytical Chemistry, 2005, 77, 5356-5363.	6.5	60
120	Increased Levels of Ubiquitin in the 6-OHDA-Lesioned Striatum of Rats. Journal of Proteome Research, 2005, 4, 223-226.	3.7	36
121	Capillary electrophoresis coupled to mass spectrometry from a polymer modified poly(dimethylsiloxane) microchip with an integrated graphite electrospray tip. Analyst, The, 2005, 130, 193-199.	3.5	63
122	Molecular Profiling of Experimental Parkinson's Disease:Â Direct Analysis of Peptides and Proteins on Brain Tissue Sections by MALDI Mass Spectrometry. Journal of Proteome Research, 2004, 3, 289-295.	3.7	162
123	In vivoprocessing of LVV-hemorphin-7 in rat brain and blood utilizing microdialysis combined with electrospray mass spectrometry. Rapid Communications in Mass Spectrometry, 2003, 17, 838-844.	1.5	27
124	Peptidomics-Based Discovery of Novel Neuropeptides. Journal of Proteome Research, 2003, 2, 213-219.	3.7	238
125	Acute and repeated treatment with l-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Research, 2002, 955, 8-15.	2.2	22
126	A neuroproteomic approach to targeting neuropeptides in the brain. Proteomics, 2002, 2, 447.	2.2	110

#	Article	IF	Citations
127	Identification of glucuronide conjugates of ketobemidone and its phase I metabolites in human urine utilizing accurate mass and tandem time-of-flight mass spectrometry. Journal of Mass Spectrometry, 2002, 37, 414-420.	1.6	33
128	Determination of extracellular release of neurotensin in discrete rat brain regions utilizing in vivo microdialysis/electrospray mass spectrometry. Brain Research, 1999, 845, 123-129.	2.2	68
129	Simultaneous analysis of endogenous neurotransmitters and neuropeptides in brain tissue using capillary electrophoresis â€" microelectrospray-tandem mass spectrometry. Electrophoresis, 1999, 20, 1527-1532.	2.4	57
130	Combining solid-phase preconcentration, capillary electrophoresis and off-line matrix-assisted laser desorption/ionization mass spectrometry: intracerebral metabolic processing of peptide Ein vivo. Journal of Mass Spectrometry, 1999, 34, 377-383.	1.6	60
131	Combining solid-phase preconcentration, capillary electrophoresis and off-line matrix-assisted laser desorption/ionization mass spectrometry: intracerebral metabolic processing of peptide E in vivo This paper is dedicated to the memory of Professor Dr Wilhelm J. Richter. Journal of Mass Spectrometry, 1999, 34, 377.	1.6	1
132	Chiral separation of local anaesthetics by a capillary electrophoresis/partial filling technique coupled on-line to micro-electrospray mass spectrometry. Journal of Mass Spectrometry, 1998, 33, 183-186.	1.6	69
133	Specific molecular mass detection of endogenously released neuropeptides using in vivo microdialysis/mass spectrometry. Journal of Neuroscience Methods, 1995, 62, 141-147.	2.5	90
134	Analysis of the Peptidomes of Amphibian Skin Granular Gland Secretionsâ€"An Integrated Functional Genomic Strategy. , 0, , 1-23.		1
135	Affinity Peptidomics Approach to Protein Detection, Quantification, and Protein Affinity Assays: Application to Forensics and Biometrics. , 0, , 191-231.		0
136	Selective Depletion and Enrichment Methods for the Analysis of Protein and Peptide Pools. , 0, , 233-264.		0
137	Detection of Target Peptides in Foods and Feeds by Mass Spectrometry. , 0, , 265-290.		0
138	Quantification of Polypeptides by Mass Spectrometry. , 0, , 291-316.		1
139	Biomarker Discovery. , 0, , 317-339.		0
140	Can Peptidomics Provide a Useful Approach for the Identification of Biomarkers of Toxicological Exposure or Effect?. , 0, , 341-353.		0
141	Peptidomics in Neuroendocrine Research: ACaenorhabditis elegans andMus musculus Study. , 0, , 355-386.		1
142	Peptidomics and Biology: Two Scientific Disciplines Driving Each Other. , 0, , 387-396.		1
143	A Short History of Insect (Neuro)Peptidomicsâ€"A Personal Story of the Birth and Youth of an Excellent Model for Studying Peptidome Biology. , 0, , 25-54.		3
144	Peptidomics of Short Linear Cytolytic Peptides from Spider Venom. , 0, , 55-70.		0

#	Article	IF	Citations
145	Molecular Cloning Approaches to Peptidomics: The Identification of Novel cDNAs Encoding Neurotoxin-Like Peptide Pools. , 0, , 71-97.		0
146	Wheat Antimicrobial Peptides. , 0, , 99-117.		0
147	Immunopeptidomics: Applications to Dissect Immune Responses through Proteomic-Based Approaches. , 0, , 119-137.		0
148	Peptidomics Approach to Proteomics. , 0, , 153-175.		1
149	The Importance of Sample Handling in Neuropeptidomics. , 0, , 177-189.		2